Transaction made with intent to develop new drugs, company says.
Kyowa Kirin Co., Ltd announced in a company press release that it will officially acquire Orchard Therapeutics for the price of $16 per American depository share (ADS) in cash, equaling a total of $387.4 million. Orchard shareholders will hold an additional contingent value right (CVR) of $1.00 per ADS. An additional $1.00 CVR will be paid for a total of $17.00 per ADS, or approximately $477.6 million if conditions are met.
According to Kyowa Kirin, the purchase will enable them to efficiently accelerate the development of multiple early research programs, including a severe, genetic form of Crohn’s disease and frontotemporal dementia (FTD).
“We are excited to announce that we have signed the Transaction Agreement to acquire Orchard Therapeutics, one of the leading providers of HSC gene therapy.” said Takeyoshi Yamashita, PhD, director of the board, chief medical officer, senior managing executive officer, Kyowa Kirin, in a company press release. “With this transaction, we anticipate being able to use a new modality that can have a profound impact on patients' lives. Orchard Therapeutics is a company with a steady track record in this field and has already launched its HSC gene therapy in Europe and filed for review in the US. Our hope is to combine the strengths of Kyowa Kirin and Orchard Therapeutics with mutual respect to realize the successful creation and delivery of life-changing value for patients living with rare and life-threatening inherited diseases.”
Reference: Kyowa Kirin to Acquire Orchard Therapeutics. Kyowa Kirin. October 5, 2023. Accessed October 5, 2023. https://www.kyowakirin.com/media_center/news_releases/2023/pdf/e20231005_02.pdf
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.